Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of IC14 in Arrhythmogenic Cardiomyopathy
NCT06275893Phase 2Completed
- Sponsor
- Implicit Bioscience
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atibuclimab in arrhythmogenic cardiomyopathy (ACM), sponsored by Implicit Bioscience. Started Mar 2024; status: completed.
02
Drugs
atibuclimab
03
Conditions
arrhythmogenic cardiomyopathy (ACM)
Beyond the preview
Go deeper on NCT06275893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275893.